Abstract: Recent demographic trends show a significant rise in both the incidence of bone-related diseases and the associated societal concern, driven by an increasingly aging population. Given the dense structure and low blood flow of bone tissue, the permeation efficiency of drugs into bone tissue after systemic administration is relatively low. As a result, the concept of "bone-targeted drugs" has emerged. Bone-targeted drugs enable drugs to quickly access to diseased bone tissue, greatly enhancing drugs therapy effects and reducing the occurrence of adverse reactions. Currently, there are numerous innovative design schemes and application strategies for bone-targeted drugs, often utilizing bisphosphonates, tetracyclines, and aspartic acid oligopeptide substances to develop new bone-targeted drug delivery systems and coupled targeted drugs. This article reviewed the literature and research on bone-targeted drugs, summarizeed the recent progress in design strategies, preparation processes, and pharmacological effects of new bone-targeted drugs, provided novel treatment ideas and designed strategies for the management of bone related diseases.